Smoking does not Alter the Therapy Response to Systemic Anti-psoriatic Therapies: A Two-country, Multi-centre, Prospective, Non-interventional Study.

Anzengruber, Florian; Augustin, Matthias; Radtke, Marc A; Thaci, Diamant; Yawalkar, Nikhil; Streit, Markus; Reich, Kristian; Drach, Mathias; Sorbe, Christina; French, Lars E; Mrowietz, Ulrich; Maul, Julia-Tatjana; Itin, Peter H; Navarini, Alexander A (2019). Smoking does not Alter the Therapy Response to Systemic Anti-psoriatic Therapies: A Two-country, Multi-centre, Prospective, Non-interventional Study. Acta dermato-venereologica, 99(10), pp. 871-877. Society for the Publication of the Acta dermato-venereologica 10.2340/00015555-3221

[img]
Preview
Text
5488.pdf - Published Version
Available under License Creative Commons: Attribution-Noncommercial (CC-BY-NC).

Download (2MB) | Preview

Psoriasis can involve the skin, joints, nails and cardiovascular system and result in a significant impairment in quality of life. Studies have shown a lower response rate to systemic anti-psoriatic therapies in smokers, and smoking is a trigger factor for psoriasis. The aim of this study was therefore to analyse the response to systemic therapies for psoriasis, with a focus on smoking. Prospectively collected data from patients with moderate to severe psoriasis included in the national psoriasis registries for Germany and Switzerland (PsoBest and SDNTT) were analysed. Therapy response was defined as reaching a Psoriasis Area and Severity Index (PASI) reduction of 75%, PASI ≤ 3 or Dermatology Life Quality Index (DLQI) ≤ 1. Out of 5,346 patients included in these registries, 1,264 met the inclusion criteria for this study. In the smoking group, 715 (60.6%) reached therapy response at month 3, compared with 358 (63.7%) in the non-smoking group (p ≤ 0.269), 659 (74.1%) vs. 330 (77%) reached therapy response at month 6 (p ≤ 0.097), and 504 (76.6%) vs. 272 (79.0%) at month 12 (p ≤ 0.611). Therefore, these data do not show that smoking affects the response rate of anti-psoriatic therapy after 3, 6 and 12 months.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Dermatology

UniBE Contributor:

Yawalkar, Nikhil

Subjects:

600 Technology > 610 Medicine & health

ISSN:

0001-5555

Publisher:

Society for the Publication of the Acta dermato-venereologica

Language:

English

Submitter:

Sandra Nyffenegger

Date Deposited:

30 Dec 2019 08:47

Last Modified:

30 Dec 2019 08:47

Publisher DOI:

10.2340/00015555-3221

PubMed ID:

31099404

Uncontrolled Keywords:

acitretin adalimumab apremilast ciclosporin etanercept fumaric acid esters infliximab methotrexate nicotine psoriasis secukinumab treatment response ustekinumab tobacco

BORIS DOI:

10.7892/boris.136786

URI:

https://boris.unibe.ch/id/eprint/136786

Actions (login required)

Edit item Edit item
Provide Feedback